Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology.

ChatGPT Ethics Global Large language models OpenAI Survey Urology

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
03 Nov 2023
Historique:
received: 29 05 2023
revised: 27 09 2023
accepted: 24 10 2023
medline: 6 11 2023
pubmed: 6 11 2023
entrez: 5 11 2023
Statut: aheadofprint

Résumé

Since its release in November 2022, ChatGPT has captivated society and shown potential for various aspects of health care. To investigate potential use of ChatGPT, a large language model (LLM), in urology by gathering opinions from urologists worldwide. An open web-based survey was distributed via social media and e-mail chains to urologists between April 20, 2023 and May 5, 2023. Participants were asked to answer questions related to their knowledge and experience with artificial intelligence, as well as their opinions of potential use of ChatGPT/LLMs in research and clinical practice. Data are reported as the mean and standard deviation for continuous variables, and the frequency and percentage for categorical variables. Charts and tables are used as appropriate, with descriptions of the chart types and the measures used. The data are reported in accordance with the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). A total of 456 individuals completed the survey (64% completion rate). Nearly half (47.7%) reported that they use ChatGPT/LLMs in their academic practice, with fewer using the technology in clinical practice (19.8%). More than half (62.2%) believe there are potential ethical concerns when using ChatGPT for scientific or academic writing, and 53% reported that they have experienced limitations when using ChatGPT in academic practice. Urologists recognise the potential of ChatGPT/LLMs in research but have concerns regarding ethics and patient acceptance. There is a desire for regulations and guidelines to ensure appropriate use. In addition, measures should be taken to establish rules and guidelines to maximise safety and efficiency when using this novel technology. A survey asked 456 urologists from around the world about using an artificial intelligence tool called ChatGPT in their work. Almost half of them use ChatGPT for research, but not many use it for patients care. The resonders think ChatGPT could be helpful, but they worry about problems like ethics and want rules to make sure it's used safely.

Sections du résumé

BACKGROUND BACKGROUND
Since its release in November 2022, ChatGPT has captivated society and shown potential for various aspects of health care.
OBJECTIVE OBJECTIVE
To investigate potential use of ChatGPT, a large language model (LLM), in urology by gathering opinions from urologists worldwide.
DESIGN, SETTING, AND PARTICIPANTS METHODS
An open web-based survey was distributed via social media and e-mail chains to urologists between April 20, 2023 and May 5, 2023. Participants were asked to answer questions related to their knowledge and experience with artificial intelligence, as well as their opinions of potential use of ChatGPT/LLMs in research and clinical practice.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS METHODS
Data are reported as the mean and standard deviation for continuous variables, and the frequency and percentage for categorical variables. Charts and tables are used as appropriate, with descriptions of the chart types and the measures used. The data are reported in accordance with the Checklist for Reporting Results of Internet E-Surveys (CHERRIES).
RESULTS AND LIMITATIONS CONCLUSIONS
A total of 456 individuals completed the survey (64% completion rate). Nearly half (47.7%) reported that they use ChatGPT/LLMs in their academic practice, with fewer using the technology in clinical practice (19.8%). More than half (62.2%) believe there are potential ethical concerns when using ChatGPT for scientific or academic writing, and 53% reported that they have experienced limitations when using ChatGPT in academic practice.
CONCLUSIONS CONCLUSIONS
Urologists recognise the potential of ChatGPT/LLMs in research but have concerns regarding ethics and patient acceptance. There is a desire for regulations and guidelines to ensure appropriate use. In addition, measures should be taken to establish rules and guidelines to maximise safety and efficiency when using this novel technology.
PATIENT SUMMARY RESULTS
A survey asked 456 urologists from around the world about using an artificial intelligence tool called ChatGPT in their work. Almost half of them use ChatGPT for research, but not many use it for patients care. The resonders think ChatGPT could be helpful, but they worry about problems like ethics and want rules to make sure it's used safely.

Identifiants

DOI: 10.1016/j.eururo.2023.10.014 PMID: 37926642
pubmed: 37926642
pii: S0302-2838(23)03211-6
doi: 10.1016/j.eururo.2023.10.014
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Michael Eppler (M)

USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; AI Center, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA.

Conner Ganjavi (C)

USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; AI Center, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA.

Lorenzo Storino Ramacciotti (LS)

USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; AI Center, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA.

Pietro Piazza (P)

Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Severin Rodler (S)

Department of Urology, Klinikum der Universität München, Munich, Germany.

Enrico Checcucci (E)

Department of Surgery, FPO-IRCCS Candiolo Cancer Institute, Candiolo, Italy.

Juan Gomez Rivas (J)

Department of Urology, Clinico San Carlos University Hospital, Madrid, Spain.

Karl F Kowalewski (KF)

Department of Urology, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.

Ines Rivero Belenchón (IR)

Urology and Nephrology Department, Virgen del Rocío University Hospital, Seville, Spain.

Stefano Puliatti (S)

Urology Department, University of Modena and Reggio Emilia, Modena, Italy.

Mark Taratkin (M)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Alessandro Veccia (A)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Loïc Baekelandt (L)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Jeremy Y-C Teoh (JY)

Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.

Bhaskar K Somani (BK)

University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Marcelo Wroclawski (M)

Hospital Israelita Albert Einstein, São Paulo, Brazil; Beneficência Portuguesa de São Paulo, São Paulo, Brazil; Faculdade de Medicina do ABC, Santo Andre, Brazil.

Andre Abreu (A)

USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; AI Center, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA.

Francesco Porpiglia (F)

Department of Surgery, FPO-IRCCS Candiolo Cancer Institute, Candiolo, Italy.

Inderbir S Gill (IS)

USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; AI Center, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA.

Declan G Murphy (DG)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.

David Canes (D)

Division of Urology, Lahey Hospital & Medical Center, Burlington, MA, USA.

Giovanni E Cacciamani (GE)

USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; AI Center, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA. Electronic address: giovanni.cacciamani@med.usc.edu.

Classifications MeSH